- Home
- AVIR vs EOLS Comparison
AVIR vs EOLS Comparison
Compare AVIR & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVIR | EOLS |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 434.5M | 407.0M |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | AVIR | EOLS |
|---|---|---|
| Price | $4.57 | $7.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $10.00 | ★ $15.50 |
| AVG Volume (30 Days) | 259.4K | ★ 724.2K |
| Earning Date | 05-11-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.00 | 1.23 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $351,367,000.00 | $297,176,000.00 |
| Revenue This Year | N/A | $13.27 |
| Revenue Next Year | N/A | $17.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 11.61 |
| 52 Week Low | $2.78 | $3.86 |
| 52 Week High | $6.45 | $10.20 |
Technical Indicators
Market Signals| Indicator | AVIR | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 51.59 | 64.07 |
| Support Level | $4.14 | $5.95 |
| Resistance Level | $4.59 | $7.20 |
| Average True Range (ATR) | 0.18 | 0.37 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 94.44 | 90.45 |
Price Performance
Historical ComparisonAbout AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
About EOLS Evolus Inc.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.